Ellume is an Australian-based digital diagnostics company that develops, manufactures and commercializes high-performance, connected products for health professionals and consumers. The company focuses on the detection of common illnesses which affect the global population and our products differ from conventional diagnostics through performance, digital connectivity, actionability and simplicity. Ellume has developed novel detection technology powered by a unique quantum dot nanoparticle, which integrates optics, electronics, biologics and software into an intuitive and high-performance digital platform.
It has a global partnership in consumer health with GlaxoSmithKline, a global partnership with QIAGEN in latent tuberculosis, and a range of professional products under the ellume·lab brand which are scheduled for US launch in 2020.
How is the company combating the flu?
At the end of 2018, Ellume formed strategic partnership with GSK Consumer healthcare, one of the world’s leading over-the-counter healthcare companies, to explore the development of a home flu test as well as other products. The company is focused on developing innovative products which enable effective and efficient healthcare for common, burdensome illness where early accurate diagnosis could significantly improve patient outcomes. Ellume products are distinguished by their technical performance, ease of use, rapid time to result and connectivity.
Commenting on the strategic partnership, Ellume’s Founder and Managing Director, Dr Sean Parsons said, “At Ellume, we pride ourselves on creating new products based on world-class science and technology, so we’re pleased to be partnering with the global leader in the field to bring this great science to a global audience where it can have maximum impact on people’s lives.”
Who has the company brought on board to further growth?
Last month, Ellume announced the appointment of David Green as Chief Financial Officer and Company Secretary, and Mark Boyle Chief Business Officer of the Company. These appointments strengthen the management of the company in preparation for US commercialisation and potential ASX IPO later this year.
David Green has over 25 years’ experience in senior finance roles covering private treaty and public company transactions, with a strong background in pre-IPO and start-up businesses. David commenced his career with EY in both England and Australia, and has since gone on to CFO roles with a number of ASX listed entities including Sigma Pharmaceuticals and Alchemia Limited. He has also worked alongside CEOs in capital raising activities including seed funding and IPOs.
Mark Boyle brings over 20 years’ of executive management experience in in-vitro diagnostic and biotechnology markets to his new role in the US. Previously, he was the President of Cellestis Inc. and continued on through the acquisition by Qiagen to successfully lead the company’s global business portfolio in tuberculosis management.
During his tenure from 2001 to 2016, sales of QuantiFERON diagnostics grew to more than AUD $150M in recurring revenue. More recently, Mark was President IVD, with Clinical Genomics. Mark is based in Valencia, California. “Mark and David both bring formidable experience and leadership to our expanding team,” said Dr Parsons.
“Mark’s experience in successfully scaling the sales of QuantiFERON in the US gives us confidence and a successful framework as we prepare to replicate this with our ellume·lab product, and David’s experience with public markets at Sigma, Alchemia and others is proving fundamental as we position the company to potentially transition onto the ASX later this year.”
Read the original article on Anthill Magazine.